SRPT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Sarepta Therapeutics Reports Q3 2026 Financial Results and Corporate Updates

Nov 5, 2026

8-K

Sarepta Therapeutics Enters Settlement Agreement to Resolve Patent Infringement Litigations

Sep 23, 2026

8-K

Sarepta Therapeutics Reports Q2 2026 Financial Results and Appoints New CEO

Aug 5, 2026

8-K

Sarepta Therapeutics Appoints Michael Severino, M.D., as Chief Executive Officer

Jul 27, 2026

8-K

Sarepta Therapeutics Announces Results of 2026 Annual Meeting of Stockholders

Jun 4, 2026

8-K

Sarepta Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

May 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

6,172,840 Shares-

Oct 15, 2021

424B5

Common Stock-

Oct 12, 2021

424B5

2,604,167 Shares

Mar 7, 2019

424B5

$350,000,000 Common Stock Prospectus Supplement Goldman Sachs & Co. LLC Morgan Stanley

Mar 5, 2019

424B5

3,817,000 Shares

Nov 9, 2018

424B5

Common Stock

Nov 8, 2018

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 28, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 4, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2025

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Mar 3, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2024

S-8 POS

Registration

Mar 28, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Wong Ryan Ho-Yan (Reporting)

Sep 8, 2026

Estepan Ian Michael (Reporting)

Sep 8, 2026

Rothfuss Cristin (Reporting)

Sep 8, 2026

Rodino-Klapac Louise (Reporting)

Sep 8, 2026

13F-HR

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Aug 13, 2026

SCHEDULE 13G/A

AQR CAPITAL MANAGEMENT LLC (Filed by)

Aug 13, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Apr 16, 2020

CORRESP

Form CORRESP - Correspondence

Apr 15, 2020

LETTER

Form UPLOAD - SEC-generated letter

Apr 13, 2020

CT ORDER

Form CT ORDER - Confidential treatment order

Nov 9, 2018

CT ORDER

Form CT ORDER - Confidential treatment order

Sep 7, 2017

CT ORDER

Form CT ORDER - Confidential treatment order

Jan 19, 2017

Sarepta Therapeutics, Inc. SRPT · SEC Filings